JP2021532114A - 放射線曝露及び化学物質曝露の慢性影響を治療するための方法及び組成物 - Google Patents

放射線曝露及び化学物質曝露の慢性影響を治療するための方法及び組成物 Download PDF

Info

Publication number
JP2021532114A
JP2021532114A JP2021503581A JP2021503581A JP2021532114A JP 2021532114 A JP2021532114 A JP 2021532114A JP 2021503581 A JP2021503581 A JP 2021503581A JP 2021503581 A JP2021503581 A JP 2021503581A JP 2021532114 A JP2021532114 A JP 2021532114A
Authority
JP
Japan
Prior art keywords
age
seq
antibody
composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021503581A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021532114A5 (https=
Inventor
ルイス エス． グルバー
Original Assignee
シワ コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シワ コーポレーション filed Critical シワ コーポレーション
Publication of JP2021532114A publication Critical patent/JP2021532114A/ja
Publication of JP2021532114A5 publication Critical patent/JP2021532114A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2021503581A 2018-07-23 2019-07-23 放射線曝露及び化学物質曝露の慢性影響を治療するための方法及び組成物 Pending JP2021532114A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862702229P 2018-07-23 2018-07-23
US62/702,229 2018-07-23
PCT/US2019/043071 WO2020023532A1 (en) 2018-07-23 2019-07-23 Methods and compositions for treating chronic effects of radiation and chemical exposure

Publications (2)

Publication Number Publication Date
JP2021532114A true JP2021532114A (ja) 2021-11-25
JP2021532114A5 JP2021532114A5 (https=) 2023-05-26

Family

ID=67777383

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021503581A Pending JP2021532114A (ja) 2018-07-23 2019-07-23 放射線曝露及び化学物質曝露の慢性影響を治療するための方法及び組成物

Country Status (4)

Country Link
US (1) US20220175916A1 (https=)
EP (1) EP3826670A1 (https=)
JP (1) JP2021532114A (https=)
WO (1) WO2020023532A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2553225C2 (ru) 2008-05-23 2015-06-10 Сива Корпорейшн Способ облегчения регенерации
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
EP3194439B1 (en) 2014-09-19 2022-01-19 Siwa Corporation Anti-age antibodies for treating inflammation and auto-immune disorders
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
HUE058854T2 (hu) 2016-02-19 2022-09-28 Siwa Corp Módszer és készítmény a rák kezelésére, az áttétes rákos sejtek elpusztítására és a rák áttétképzõdésének megelõzésére a fejlett glikációs végtermékek (AGE) elleni antitest alkalmazásával
KR20180133452A (ko) 2016-04-15 2018-12-14 시와 코퍼레이션 신경퇴행성 질환을 치료하기 위한 항-노화 항체
JP2019518763A (ja) 2016-06-23 2019-07-04 シワ コーポレーション 様々な疾患及び障害の治療において使用するためのワクチン
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
CA3059803A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
US20230181730A1 (en) * 2020-05-01 2023-06-15 Siwa Corporation Methods of treating infections
WO2022093195A1 (en) * 2020-10-27 2022-05-05 Siwa Corporation Methods and compositions for treating osteoarthritis using anti-age antibodies or age antigens
WO2022125776A2 (en) * 2020-12-09 2022-06-16 Siwa Corporation Methods and compositions for treating kidney diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015502366A (ja) * 2011-12-13 2015-01-22 バック インスティテュート フォー リサーチ オン エイジング 薬物療法を改善するための方法
WO2017065837A1 (en) * 2015-10-13 2017-04-20 Siwa Corporation Anti-age antibodies and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5624804A (en) 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
US6387373B1 (en) 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
US6380165B1 (en) 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
EP1988918A4 (en) 2006-02-22 2010-04-28 Novavax Inc ADJUVANZ AND VACCINE COMPOSITIONS
RU2553225C2 (ru) * 2008-05-23 2015-06-10 Сива Корпорейшн Способ облегчения регенерации
ES2725852T3 (es) * 2010-09-27 2019-09-27 Siwa Corp Eliminación selectiva de células modificadas por AGE para el tratamiento de la aterosclerosis
EP3194439B1 (en) * 2014-09-19 2022-01-19 Siwa Corporation Anti-age antibodies for treating inflammation and auto-immune disorders
HUE058854T2 (hu) * 2016-02-19 2022-09-28 Siwa Corp Módszer és készítmény a rák kezelésére, az áttétes rákos sejtek elpusztítására és a rák áttétképzõdésének megelõzésére a fejlett glikációs végtermékek (AGE) elleni antitest alkalmazásával
JP2019518763A (ja) * 2016-06-23 2019-07-04 シワ コーポレーション 様々な疾患及び障害の治療において使用するためのワクチン
CA3059803A1 (en) * 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US20200150131A1 (en) * 2017-05-04 2020-05-14 Siwa Corporation Diagnostic advanced glycation end-product antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015502366A (ja) * 2011-12-13 2015-01-22 バック インスティテュート フォー リサーチ オン エイジング 薬物療法を改善するための方法
WO2017065837A1 (en) * 2015-10-13 2017-04-20 Siwa Corporation Anti-age antibodies and methods of use thereof

Also Published As

Publication number Publication date
US20220175916A1 (en) 2022-06-09
WO2020023532A1 (en) 2020-01-30
EP3826670A1 (en) 2021-06-02

Similar Documents

Publication Publication Date Title
JP2021532114A (ja) 放射線曝露及び化学物質曝露の慢性影響を治療するための方法及び組成物
US10858449B1 (en) Methods and compositions for treating osteoarthritis
KR102786111B1 (ko) 고급 당화 최종 산물(age)에 대한 항체를 사용하여 암을 치료하고, 전이성 암 세포를 사멸시키고, 암 전이를 예방하기 위한 방법 및 조성물
US10961321B1 (en) Methods and compositions for treating pain associated with inflammation
CN105999293B (zh) Cd37结合分子及其免疫缀合物
JP2021534144A (ja) Ａｇｅ修飾細胞を除去するための、抗カルボキシメチルリシン抗体及び超音波
WO2022093195A1 (en) Methods and compositions for treating osteoarthritis using anti-age antibodies or age antigens
US20210253737A1 (en) Methods and compositions for treating disease-related cachexia
WO2021247397A2 (en) Methods and compositions for enhancing the immune system
CN115996954A (zh) 治疗感染的方法
KR102296017B1 (ko) 혈관 질환 및 이에 따른 합병증 치료
WO2015092077A1 (en) Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor
WO2006066171A1 (en) Amyloid βετα antibodies for use in improving cognition
EP4388016A1 (en) Methods and compositions for treating fibrotic diseases
US11518801B1 (en) Methods and compositions for treating diabetes and diabetic complications
US20240000930A1 (en) Methods and compositions for treating kidney diseases
CN109414426A (zh) 使用精氨酸耗竭剂的组合癌症免疫疗法
CN113412130A (zh) 用于诊断和治疗癌症及其他疾病的对促肿瘤癌症相关成纤维细胞的识别和靶向
WO2024102157A1 (en) Methods and compositions for treating diabetes and diabetic complications
KR102654035B1 (ko) 도펠 단백질 억제제
WO2025137236A1 (en) Compositions and methods for modulating cdcp1 mediated signal transduction
RU2822457C2 (ru) Моноклональные антитела против вируса бешенства и их смесь
JP5822407B2 (ja) 軟骨・骨破壊抑制剤
HK40116844A (zh) 抗转甲状腺素蛋白抗体、其组合物、试剂盒、方法和用途
JP2014091687A (ja) 軟骨又は骨の破壊の診断薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230424

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230428

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230518

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230712

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230914

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231106